Motley Fool
Got $5,000? TransMedics Could Be a High‑Tech Organ Transplant Moonshot
📈
AI Sentiment
Highly Positive
8/10
- Home
- TMDX
as of 03-06-2026 3:40pm EST
$129.58
$10.49
-7.49%
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System(OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The Company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.
| Founded: | 1998 | Country: | United States |
| Employees: | N/A | City: | ANDOVER |
| Market Cap: | 4.6B | IPO Year: | 2019 |
| Target Price: | $152.33 | AVG Volume (30 days): | 757.9K |
| Analyst Decision: | Buy | Number of Analysts: | 9 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | semi-annual |
| EPS: | 4.87 | EPS Growth: | 382.18 |
| 52 Week Low/High: | $62.42 - $156.00 | Next Earning Date: | 06-01-2026 |
| Revenue: | $605,494,000 | Revenue Growth: | 37.13% |
| Revenue Growth (this year): | 24.12% | Revenue Growth (next year): | 18.69% |
| P/E Ratio: | 28.89 | Index: | N/A |
| Free Cash Flow: | 133.6M | FCF Growth: | N/A |
AI-Powered TMDX Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated a day ago
AI Recommendation
hold
Model Accuracy: 79.75%
79.75%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of TransMedics Group Inc. (TMDX)
Hernandez Gerardo
Sell
Chief Financial Officer
TMDX Mar 4, 2026
Avg Cost/Share
$147.21
Shares
7,236
Total Value
$1,065,211.56
Owned After
14,689
Corcoran Nicholas
Sell
See remarks
TMDX Mar 2, 2026
Avg Cost/Share
$139.12
Shares
2,966
Total Value
$412,629.92
Owned After
29,831
SEC Form 4
Ranganath Anil P.
Sell
See remarks
TMDX Mar 2, 2026
Avg Cost/Share
$139.12
Shares
864
Total Value
$120,199.68
Owned After
13,091
SEC Form 4
Hernandez Gerardo
Sell
Chief Financial Officer
TMDX Mar 2, 2026
Avg Cost/Share
$139.12
Shares
375
Total Value
$52,170.00
Owned After
14,689
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Hernandez Gerardo | TMDX | Chief Financial Officer | Mar 4, 2026 | Sell | $147.21 | 7,236 | $1,065,211.56 | 14,689 | |
| Corcoran Nicholas | TMDX | See remarks | Mar 2, 2026 | Sell | $139.12 | 2,966 | $412,629.92 | 29,831 | |
| Ranganath Anil P. | TMDX | See remarks | Mar 2, 2026 | Sell | $139.12 | 864 | $120,199.68 | 13,091 | |
| Hernandez Gerardo | TMDX | Chief Financial Officer | Mar 2, 2026 | Sell | $139.12 | 375 | $52,170.00 | 14,689 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 27, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 27, 2026 · 100% conf.
AI Prediction SELL
1D
-4.08%
$138.45
5D
-13.19%
$125.31
20D
-12.51%
$126.29
Price: $144.35 Prob +5D: 0% AUC: 1.000
0001193125-26-079392
8-K
false 0001756262 0001756262 2026-02-27 2026-02-27
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2026
TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter)
Massachusetts
001-38891
83-2181531
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
200 Minuteman Road
Andover, Massachusetts
01810
(Address of Principal Executive Offices)
(Zip Code) Registrant’s Telephone Number, Including Area Code: (978) 552-0900 (Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, no par value per share
TMDX
The Nasdaq Global Market Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 27, 2026, TransMedics Group, Inc. (the “Company”) issued a press release announcing additional information on the impact of the release of the Company’s U.S. valuation allowance on deferred tax assets on the Company’s previously reported financial results for the quarter ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by TransMedics Group, Inc. on February 27, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Date: February 27, 2026
TRANSMEDICS GROUP, INC.
By:
/s/ Gerardo Hernandez
Name:
Gerardo Hernandez
Title:
Chief Financial Officer and Treasurer
2025 Q4 Q4 2025 Earnings
8-K SELL Feb 24, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLFeb 24, 2026 · 100% conf.
AI Prediction SELL
1D
-4.08%
$138.45
5D
-13.19%
$125.31
20D
-12.51%
$126.29
Price: $144.35 Prob +5D: 0% AUC: 1.000
0001193125-26-066953
8-K
0001756262false00017562622026-02-242026-02-24
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): February 24, 2026
TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter)
Massachusetts
001-38891
83-2181531
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
200 Minuteman Road
Andover, Massachusetts
01810
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (978) 552-0900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, no par value per share
TMDX
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On February 24, 2026, TransMedics Group, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter and year ended December 31, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by TransMedics Group, Inc. on February 24, 2026
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRANSMEDICS GROUP, INC.
Date:
February 24, 2026
By:
/s/ Gerardo Hernandez
Name: Gerardo Hernandez Title: Chief Financial Officer and Treasurer
2025 Q3 Q3 2025 Earnings
8-K Oct 29, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 29, 2025
0001193125-25-256326
8-K
false000175626200017562622025-10-292025-10-29
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): October 29, 2025
TransMedics Group, Inc. (Exact name of Registrant as Specified in Its Charter)
Massachusetts
001-38891
83-2181531
(State or Other Jurisdiction of Incorporation)
(Commission File Number)
(IRS Employer Identification No.)
200 Minuteman Road
Andover, Massachusetts
01810
(Address of Principal Executive Offices)
(Zip Code)
Registrant’s Telephone Number, Including Area Code: (978) 552-0900
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) Securities registered pursuant to Section 12(b) of the Act:
Title of each class
Trading Symbol(s)
Name of each exchange on which registered
Common Stock, no par value per share
TMDX
The Nasdaq Global Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02 Results of Operations and Financial Condition. On October 29, 2025, TransMedics Group, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended September 30, 2025. A copy of this press release is furnished as Exhibit 99.1 and is incorporated herein by reference. The information in this Form 8-K (including Exhibit 99.1 attached hereto) is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company, under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing. Item 9.01. Financial Statements and Exhibits. (d) Exhibits
Exhibit No.
Description
99.1
Press release issued by TransMedics Group, Inc. on October 29, 2025
104
Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
TRANSMEDICS GROUP, INC.
Date:
October 29, 2025
By:
/s/ Gerardo Hernandez
Name: Gerardo Hernandez Title: Chief Financial Officer and Treasurer
Latest TransMedics Group Inc. News
TMDX Breaking Stock News: Dive into TMDX Ticker-Specific Updates for Smart Investing
Compare TMDX vs Leading Stocks
See how TMDX stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "TMDX TransMedics Group Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.